Cargando…
Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097451/ https://www.ncbi.nlm.nih.gov/pubmed/37065010 http://dx.doi.org/10.1093/rap/rkad037 |
| _version_ | 1785024581893881856 |
|---|---|
| author | Ho, Gen Nen Douglas, Karen May Jane |
| author_facet | Ho, Gen Nen Douglas, Karen May Jane |
| author_sort | Ho, Gen Nen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10097451 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100974512023-04-13 Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? Ho, Gen Nen Douglas, Karen May Jane Rheumatol Adv Pract Letter to the Editor Oxford University Press 2023-04-03 /pmc/articles/PMC10097451/ /pubmed/37065010 http://dx.doi.org/10.1093/rap/rkad037 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Letter to the Editor Ho, Gen Nen Douglas, Karen May Jane Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? |
| title | Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? |
| title_full | Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? |
| title_fullStr | Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? |
| title_full_unstemmed | Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? |
| title_short | Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? |
| title_sort | nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a uk district general hospital systemic sclerosis cohort? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10097451/ https://www.ncbi.nlm.nih.gov/pubmed/37065010 http://dx.doi.org/10.1093/rap/rkad037 |
| work_keys_str_mv | AT hogennen nintedanibforprogressivefibrosinginterstitiallungdiseasehowmanymeetcriteriainaukdistrictgeneralhospitalsystemicsclerosiscohort AT douglaskarenmayjane nintedanibforprogressivefibrosinginterstitiallungdiseasehowmanymeetcriteriainaukdistrictgeneralhospitalsystemicsclerosiscohort |